Eli Lilly delivered another powerful quarter as demand for its diabetes and obesity treatments accelerated. The results strengthen the company’s lead over Novo Nordisk, but Lilly’s trillion-dollar valuation leaves investors with little room for disappointment.
August 5, 2026
Eli Lilly shares advanced after the pharmaceutical group reported stronger-than-expected second-quarter results and raised its full-year revenue forecast, supported by exceptional demand for Mounjaro and Zepbound.
Quarterly revenue increased 48% year over year to approximately $23 billion. Adjusted earnings reached $8.38 per share, comfortably exceeding the $6.01 expected by analysts.
The two tirzepatide brands generated almost 65% of total revenue, underlining both the strength of Lilly’s position in the rapidly expanding obesity market and its growing dependence on a single molecule.
Eli Lilly’s second-quarter results at a glance
| Metric | Q2 2026 result |
|---|---|
| Revenue | $22.97 billion |
| Revenue growth | 48% |
| Adjusted EPS | $8.38 |
| Mounjaro sales | $9.94 billion |
| Mounjaro growth | 91% |
| Zepbound sales | $4.93 billion |
| Zepbound growth | 46% |
| Gross margin | 85.8% |
| New 2026 revenue guidance | $85–87 billion |
Mounjaro becomes the main growth engine
Worldwide Mounjaro revenue surged 91% to $9.94 billion, substantially ahead of market expectations. Growth was particularly strong outside the United States, where Mounjaro can be prescribed for diabetes and, in some markets, weight management.
Zepbound, the U.S. obesity brand based on the same active ingredient, generated $4.93 billion, an increase of approximately 46%. Analysts had expected around $4.73 billion.
Together, Mounjaro and Zepbound produced $14.87 billion of quarterly sales. That represents 64.7% of Lilly’s total revenue and shows how quickly tirzepatide has become one of the most commercially important medicines in the pharmaceutical industry.
The increase was primarily volume-driven. Demand expanded in the United States and internationally, more than offsetting lower realized prices caused by discounts, expanded access programs and negotiations with public healthcare systems. Eli Lilly’s second-quarter release and Reuters provide the underlying figures.
Production capacity is finally catching up with demand
Manufacturing capacity has been one of the principal constraints on the obesity-drug market. For several years, demand for injectable GLP-1 treatments exceeded the industry’s ability to produce finished doses.
Lilly has responded with an unusually large investment program spanning active pharmaceutical ingredients, injection devices, filling operations and packaging. Its expansion includes facilities in Indiana, North Carolina, Wisconsin, Virginia, Texas, Alabama and Pennsylvania, as well as sites in Ireland, Germany and the Netherlands.
In May, the company announced an additional $4.5 billion commitment to its Indiana operations, bringing its manufacturing commitments in the state since 2020 to $21 billion. An earlier expansion at Lilly’s Lebanon, Indiana, site included $9 billion dedicated partly to increasing tirzepatide production. Eli Lilly details the latest investment.
The financial results suggest these investments are beginning to translate into higher available volumes. That matters because every additional dose Lilly can manufacture has a ready market, while greater scale should progressively reduce production costs.
Capacity nevertheless remains a risk. Pharmaceutical facilities take years to build and validate, and Lilly must balance current demand for tirzepatide with the future production requirements of its expanding pipeline.
Revenue guidance raised—but profit guidance needs context
Lilly increased its 2026 revenue forecast to between $85 billion and $87 billion, compared with its previous range of $82 billion to $85 billion.
The new midpoint of $86 billion implies another year of exceptional growth and suggests management expects demand to remain resilient despite lower net prices and the arrival of competing oral treatments.
The adjusted earnings outlook was narrowed to $35.50–$36.50 per share. Although the revenue forecast improved, Lilly reduced the upper end of its previous EPS range by $0.50, primarily because of charges related to acquisitions and other business-development activity.
Investors should therefore distinguish between the operating performance of Lilly’s commercial portfolio—which was stronger than expected—and accounting expenses related to investments in future medicines.
Margins expand despite pricing pressure
Lilly’s gross profit rose 50% to $19.7 billion, while gross margin expanded by 1.5 percentage points to 85.8% of revenue.
The improvement is significant because realized prices declined during the quarter. Better manufacturing economics and a more favorable product mix more than compensated for that pressure.
This is one of the strongest elements of the earnings report. Lilly is increasing access and accepting lower average prices in selected channels, but higher volumes and production efficiency are protecting profitability.
There is still a trade-off. Wider Medicare coverage, direct-to-consumer pricing and international reimbursement agreements can expand the addressable patient population, yet they may also reduce revenue per prescription. Future margin expansion will depend on production efficiencies continuing to outpace price erosion.
The pipeline extends beyond Mounjaro and Zepbound
Lilly’s valuation is based not only on current tirzepatide sales but also on the expectation that its next generation of obesity medicines will broaden the market.
The company’s most important pipeline assets include:
- Foundayo, the brand name for Lilly’s once-daily oral GLP-1 treatment. Second-quarter sales of $98 million were slightly below expectations, although prescriptions accelerated during July. Lilly says the medicine is under regulatory review in more than 40 markets.
- Retatrutide, an experimental injectable treatment targeting three metabolic pathways. Positive Phase 3 results support Lilly’s plan to begin global registration filings, with a U.S. submission expected in the first quarter of 2027.
- Next-generation combination and muscle-preservation treatments, designed to improve weight loss, reduce side effects or help patients retain lean body mass.
Beyond obesity, Lilly continues to invest in oncology, immunology, neuroscience and genetic medicines. That diversification is important because Mounjaro and Zepbound currently account for an exceptionally large portion of group sales.
Lilly widens its lead over Novo Nordisk
The quarter reinforces Lilly’s advantage over Novo Nordisk in injectable obesity treatments.
Novo’s diabetes and obesity portfolio generated approximately $9.16 billion during the quarter, compared with nearly $14.9 billion for Mounjaro and Zepbound alone. In the United States, Zepbound prescriptions have recently been more than twice those of injectable Wegovy.
Clinical efficacy remains a major competitive advantage for tirzepatide. However, Novo has gained momentum in oral treatments: its Wegovy pill recorded roughly $497 million of quarterly sales, well above Foundayo’s early contribution, although it fell slightly short of analysts’ expectations.
Novo has also become more aggressive on pricing, marketing and product development. Both companies raised their annual outlooks, suggesting that the obesity market remains large enough to support more than one major winner. Analysts estimate that annual U.S. obesity-drug sales alone could exceed $100 billion by 2030. Reuters’ comparison of the two companies describes the increasingly intense contest.
A strong company at a demanding valuation
Following the earnings release, Lilly shares traded around $1,158, giving the company a market capitalization of approximately $1.03 trillion.
The stock was valued at roughly:
- 37 times trailing earnings;
- 27–34 times forward earnings, depending on the provider and earnings period;
- 13 times trailing revenue;
- about 88 times trailing free cash flow.
These multiples remain far above those of most large pharmaceutical companies. Lilly’s forward earnings multiple is approximately twice the broader pharmaceutical-industry median, although its expected growth rate is also considerably higher. S&P Global Market Intelligence data compiled by StockAnalysis show the premium embedded in the shares.
The valuation can be justified if tirzepatide maintains its leadership, manufacturing capacity continues to expand and the next generation of treatments succeeds. But it creates substantial downside risk if sales growth slows, pricing pressure intensifies or a major pipeline asset disappoints.
At this level, merely reporting good results may eventually be insufficient. Lilly must continue beating already elevated expectations.
What investors should watch next
The central questions for the coming quarters are:
- whether international Mounjaro growth remains as strong;
- how quickly Lilly can bring additional manufacturing capacity online;
- whether lower prices are fully offset by higher volumes;
- whether Foundayo can close the gap with oral Wegovy;
- the regulatory progress of retatrutide;
- and whether operating cash flow can keep pace with capital expenditure and acquisitions.
The bottom line
Eli Lilly’s second-quarter report confirms that Mounjaro and Zepbound remain among the most powerful growth assets in global pharmaceuticals. Strong volumes, improving manufacturing economics and an expanding patient base allowed Lilly to raise its revenue outlook while increasing gross margin.
The company is also widening its injectable-market lead over Novo Nordisk and building a pipeline that could extend its obesity franchise well beyond tirzepatide.
The principal concern is valuation. At more than $1 trillion, Lilly’s market price assumes years of rapid growth, successful capacity expansion and continued pipeline execution. The latest results support that optimistic scenario—but they also raise the performance bar for every quarter that follows.
This article is for informational purposes only and does not constitute investment advice.
